ADVERTISEMENT

Elizabeth Edwards’ Death Drives Advocates at SABCS

News of Elizabeth Edwards' death heightens a sense of urgency at the 33rd annual San Antonio Breast Cancer Symposium among patients, survivors and advocates.

BY KATHY LATOUR
PUBLISHED WEDNESDAY, DECEMBER 8, 2010
There is a sense of urgency among the 36 patient advocates gathered in a hotel meeting room before the beginning of the San Antonio Breast Cancer Symposium. Having just arrived, most are hearing for the first time about the death of Elizabeth Edwards from metastatic breast cancer.

Little is said about Edwards as the women introduce themselves, each beginning with her number of years of survivorship and some adding details, such as HER2 status and whether she is triple negative or metastatic. Then they tell of their affiliations back home where they work on research, education or policy at the community, state or national level:  SHARE, Susan G. Komen for the Cure, the National Breast Cancer Coalition, Y-ME, Young Survival Coalition, Gilda’s Club and others, as well as national organizations in Nigeria, New Zealand, Japan, Australia, Egypt and Scotland.

They have come to learn all they can to return home and effect change. Edwards’ death is an unneeded exclamation point about the importance of their mission.

The women have come on scholarship from the Alamo Breast Cancer Foundation, which for 12 years has brought patient advocates to SABCS. The program began when Charles Coltman Jr., MD, a co-founder of the symposium, approached breast cancer survivors Joy Moose and Dale Eastman about creating an advocacy program for the symposium. Coltman was well acquainted with the two women, who had begun attending the physician-only symposium to educate themselves on breast cancer research. When more advocates began appearing, he asked them to formalize an advocacy program for survivors.

“We said, ‘Yes,’ ” says Moose. “Then we got out in the hall, hugged, and said, ‘So how do we do this?’ ”

There were nine survivors in the first “class.” Today, the advocates come from 13 states and six foreign countries, their attendance covered by grants totaling more than $313,500. To date, 367 advocates have completed the program.

For the next four days, these women, all breast cancer survivors, will be listening to presentations on the latest research, with each assigned one session to write up for the educational CD that will be created for distribution across the country in early 2011. “We only take women who have already been through Project Lead,” Eastman says, referring to the intense basic science program offered by the National Breast Cancer Coalition that prepares advocates to sit on advisory and evaluative panels and boards, such as the Department of Defense Peer Reviewed Board. The advocates agree to attend a Project Lead advanced topics session, write a “hot topic” and work with mentors to help clarify their topic.

Every day has additional discussion and education sessions, meaning the woman are busy from morning to night. And even then, they often huddle in groups to share information on the latest advocacy accomplishments. No one has to remind them of the importance of their work here.

ADVERTISEMENT
Related Articles
Hope vs. Acceptance: The Metastatic Cancer See-Saw
Those of us living with metastatic cancer ride a see-saw between hope and acceptance.
Ovarian Suppression Emerges as Option for Younger, Premenopausal Breast Cancer Patients
BY JASON M. BRODERICK
Women with hormone receptor-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant Aromasin, according to results from the phase 3 SOFT trial.
Several Cancer Therapies Up for FDA Review in 2015
BY ANITA T. SHAFFER
The Food and Drug Administration’s calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.
Study Shows Women with Stage 1 HER2-Positive Breast Cancers Could Benefit from Herceptin
BY CHRISTINA IZZO
Results of a phase 2 study showed that women with small, stage 1 HER2-positive breast cancer who received a combination of lower-intensity chemotherapy and Herceptin following surgery were highly unlikely to have a recurrence.
Overcoming the Mental Battle of  Metastatic Cancer
The mental challenges of having stage 4 breast cancer are just as overwhelming as the physical ones.
Related Videos
Joan Lunden Discusses the Physical and Emotional Effects of Breast Cancer Treatment
Journalist Joan Lunden shares her experience with breast cancer, side effects and working through treatment.
Journalist Joan Lunden Discusses Her Breast Cancer Diagnosis and Treatment
Roy Firestone interviews longtime journalist, author and television host Joan Lunden on her recent breast cancer diagnosis and treatment.
Breast Oncologist Beth Overmoyer Explains Results of Ovarian Suppression
Beth Overmoyer, a breast oncologist at Dana-Farber Cancer Institute, speaks on the results of the SOFT trial and its potential impact on young women with hormone receptor-positive breast cancer.
SABCS: Debu Tripathy Discusses Hormonal Therapy Advances in Breast Cancer
Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer.
Follow Up Study Data Draws Attention to Benefit, Side Effects of Adjuvant Chemotherapy in Breast Cancer
Debu Tripathy,editor-in-chief of CURE magazine, explains the importance of chemotherapy studies presented at the 2014 San Antonio Breast Cancer Symposium, including new data on the impact of side effects.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$